Crispr Therapeutics AG (CRSP)

The total asset value of Crispr Therapeutics AG (CRSP) stood at $ 2,330 Mln as on 30-Jun-23

The share price of Crispr Therapeutics AG (CRSP) is $70.66 (NASDAQ) as of 28-Nov-2023 16:05 EST. Crispr Therapeutics AG (CRSP) has given a return of -16.54% in the last 3 years.

Crispr Therapeutics AG (CRSP) has a market capitalisation of $ 3,920 Mln as on 11-Aug-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Crispr Therapeutics AG (CRSP) is 2.01 times as on 11-Aug-2023, a -0.21% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Crispr Therapeutics AG (CRSP) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Crispr Therapeutics AG (CRSP) and enter the required number of quantities and click on buy to purchase the shares of Crispr Therapeutics AG (CRSP).

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

The CEO & director of Dr. Samarth Kulkarni Ph.D.. is Crispr Therapeutics AG (CRSP), and CFO & Sr. VP is Mr. Brendan Smith M.B.A..

The promoters of Crispr Therapeutics AG (CRSP) have pledged 0% of the total equity as on Jun-23.

Some of the close peers are:

No, TTM profit after tax of Crispr Therapeutics AG (CRSP) was $-338 Mln.